|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.10 USD | -2.17% |
|
+37.11% | +151.89% |
| 08:22am | Morgan Stanley Adjusts Silence Therapeutics PT to $32 From $25, Maintains Overweight Rating | MT |
| 07:51pm | Silence Therapeutics plc - Special Call |
Company Valuation: Silence Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 528 | 454.3 | 527.3 | 259.5 | 213.4 | 539 | - | - |
| Change | - | -13.96% | 16.08% | -50.8% | -17.76% | 152.6% | - | - |
| Enterprise Value (EV) 1 | 454.5 | 454.3 | 473.6 | 163.4 | 149.5 | 405.9 | 365 | 309.9 |
| Change | - | -0.04% | 4.24% | -65.49% | -8.53% | 171.5% | -10.09% | -15.08% |
| P/E | -13.7x | -9.99x | -11.6x | -6.95x | -3.22x | -41.7x | -18.2x | -16.8x |
| PBR | - | - | 29.5x | -7.12x | 13.8x | 15.4x | 10.4x | 8.25x |
| PEG | - | 0.8x | 4.94x | 0.2x | -0x | 0.5x | -0x | -1.98x |
| Capitalization / Revenue | 42.5x | 26x | 20.8x | 7.57x | 510x | 105x | 90.8x | 19.7x |
| EV / Revenue | 36.6x | 26x | 18.7x | 4.77x | 357x | 79.1x | 61.5x | 11.3x |
| EV / EBITDA | -10x | -9.44x | -9.64x | -3.29x | -2.2x | -9.56x | -4.31x | -2.82x |
| EV / EBIT | -9.92x | -9.35x | -9.55x | -3.26x | -2.19x | -9.46x | -4.55x | -3.12x |
| EV / FCF | 419x | -9.96x | -10.4x | -3.04x | -3x | -7.17x | -2.46x | -1.68x |
| FCF Yield | 0.24% | -10% | -9.63% | -32.9% | -33.4% | -14% | -40.6% | -59.6% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | -1.742 | -1.527 | -1.491 | -0.99 | -1.89 | -0.37 | -0.848 | -0.92 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 12.42 | 17.5 | 25.38 | 34.27 | 0.4183 | 5.129 | 5.934 | 27.42 |
| EBITDA 1 | -45.39 | -48.11 | -49.11 | -49.69 | -68.06 | -42.44 | -84.69 | -110 |
| EBIT 1 | -45.81 | -48.59 | -49.6 | -50.16 | -68.16 | -42.9 | -80.29 | -99.33 |
| Net income 1 | -39.41 | -40.49 | -43.27 | -35.89 | -66.32 | -40.52 | -84.35 | -104.9 |
| Net Debt 1 | -73.54 | - | -53.76 | -96.03 | -63.87 | -133.1 | -174 | -229.1 |
| Reference price 3 | 23.89 | 15.25 | 17.37 | 6.88 | 6.08 | 15.43 | 15.43 | 15.43 |
| Nbr of stocks (in thousands) | 29,928 | 35,893 | 38,670 | 47,215 | 47,234 | 47,234 | - | - |
| Announcement Date | 3/17/22 | 3/15/23 | 3/13/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -41.7x | 79.13x | -9.56x | - | 729M | |
| 34.04x | 6.07x | 18.06x | 0.94% | 50.03B | |
| -21.52x | 306.46x | -21.8x | -.--% | 44.36B | |
| 47.48x | 5.43x | 29.82x | -.--% | 40.82B | |
| 31.16x | 3.08x | 13.3x | -.--% | 39.83B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.51B | |
| 34.26x | 5.61x | 25.51x | -.--% | 16.81B | |
| 23.3x | 2.04x | 8.84x | 1.15% | 14.05B | |
| 74.11x | 3.92x | 15.21x | -.--% | 13.22B | |
| Average | 23.52x | 46.73x | 11.28x | 0.31% | 28.04B | |
| Weighted average by Cap. | 26.85x | 58.50x | 12.49x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLN Stock
- Valuation Silence Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
